Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
Iain B McInnesAndrew J K OstorPhillip J MeaseWilliam TillettXenofon BaraliakosKurt de VlamLouis BessetteRalph LippeAnna ManicciaDai FengTianming GaoPatrick ZuegerChristopher SafforeKoji KatoIn-Ho SongAtul DeodharPublished in: RMD open (2022)
Rapid and sustained improvements in pain outcomes across several end points were consistently shown with upadacitinib over 1 year in patients with active PsA or AS who had either inadequate response to prior non-biologic or biologic disease-modifying antirheumatic drugs (PsA studies) or were biologic-naïve with inadequate response to non-steroidal anti-inflammatory drugs (AS study).
Keyphrases
- rheumatoid arthritis
- ankylosing spondylitis
- anti inflammatory drugs
- clinical trial
- disease activity
- prostate cancer
- chronic pain
- pain management
- neuropathic pain
- rheumatoid arthritis patients
- radical prostatectomy
- open label
- study protocol
- double blind
- phase ii
- spinal cord injury
- placebo controlled
- insulin resistance
- adipose tissue
- weight loss
- sensitive detection